EntreMed, Inc.: Survival Strategy in the Turbulent Biotech Industry: Abstract
This case presents the situation facing Neil Campbell, the newly promoted President & COO of EntreMed, Inc., at the beginning of 2003. EntreMed, a U.S. biotech company, was in crisis, with several million dollars of debt that had to be restructured and an unsustainable “burn” rate (annual expenditures). EntreMed’s new management team needed to revise the overall company strategy to survive. In crafting their new strategy, the team had to manoeuvre within a complex industry environment that included a complex new drug approval process, stringent protection of intellectual property rights, and a need to attract and retain top researchers.
Teaching notes are available for teachers only. Contact the HEC Montréal Case Centre for more information.